110 related articles for article (PubMed ID: 12375699)
1. Additive effects of amrubicin with cisplatin on human lung cancer cell lines.
Yamauchi S; Kudoh S; Kimura T; Hirata K; Yoshikawa J
Osaka City Med J; 2002 Jun; 48(1):69-76. PubMed ID: 12375699
[TBL] [Abstract][Full Text] [Related]
2. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
Takigawa N; Takeyama M; Shibayama T; Tada A; Kawata N; Okada C; Aoe K; Kozuki T; Hotta K; Tabata M; Kiura K; Ueoka H; Tanimoto M; Takahashi K
Oncol Rep; 2006 Apr; 15(4):837-42. PubMed ID: 16525668
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.
Hayashi S; Hatashita M; Matsumoto H; Shioura H; Kitai R; Kano E
Int J Mol Med; 2006 Nov; 18(5):909-15. PubMed ID: 17016621
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
[TBL] [Abstract][Full Text] [Related]
10. Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction.
Hayashi S; Hatashita M; Matsumoto H; Jin ZH; Shioura H; Kano E
Int J Mol Med; 2005 Sep; 16(3):381-7. PubMed ID: 16077943
[TBL] [Abstract][Full Text] [Related]
11. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.
Hanada M; Mizuno S; Fukushima A; Saito Y; Noguchi T; Yamaoka T
Jpn J Cancer Res; 1998 Nov; 89(11):1229-38. PubMed ID: 9914793
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
13. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
14. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kasai D; Miyazaki M; Maeno K; Sato S
Cancer Chemother Pharmacol; 2011 Sep; 68(3):669-76. PubMed ID: 21128075
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Barret JM; Kruczynski A; Etiévant C; Hill BT
Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
[TBL] [Abstract][Full Text] [Related]
19. [Combination effect of caffeine and cisplatin on a cisplatin resistant human lung cancer cell line].
Ohsaki Y; Ishida S; Fujikane T; Akiba Y; Osanai S; Onodera S
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1339-43. PubMed ID: 2369137
[TBL] [Abstract][Full Text] [Related]
20. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
